The DOI matches its Crossref record; 421 of the 427 references it cites were found in a registry or an index.
Cost of disorders of the brain in Europe 2010
Open accessAbstract
Background The spectrum of disorders of the brain is large, covering hundreds of disorders that are listed in either the mental or neurological disorder chapters of the established international diagnostic classification systems. These disorders have a high prevalence as well as short- and long-term impairments and disabilities. Therefore they are an emotional, financial and social burden to the patients, their families and their social network. In a 2005 landmark study, we estimated for the first time the annual cost of 12 major groups of disorders of the brain in Europe and gave a conservative estimate of €386 billion for the year 2004. This estimate was limited in scope and conservative due to the lack of sufficiently comprehensive epidemiological and/or economic data on several important diagnostic groups. We are now in a position to substantially improve and revise the 2004 estimates. In the present report we cover 19 major groups of disorders, 7 more than previously, of an increased range of age groups and more cost items. We therefore present much improved cost estimates. Our revised estimates also now include the new EU member states, and hence a population of 514 million people.Aims To estimate the number of persons with defined disorders of the brain in Europe in 2010, the total cost per person related to each disease in terms of direct and indirect costs, and an estimate of the total cost per disorder and country.Methods The best available estimates of the prevalence and cost per person for 19 groups of disorders of the brain (covering well over 100 specific disorders) were identified via a systematic review of the published literature. Together with the twelve disorders included in 2004, the following range of mental and neurologic groups of disorders is covered: addictive disorders, affective disorders, anxiety disorders, brain tumor, childhood and adolescent disorders (developmental disorders), dementia, eating disorders, epilepsy, mental retardation, migraine, multiple sclerosis, neuromuscular disorders, Parkinson's disease, personality disorders, psychotic disorders, sleep disorders, somatoform disorders, stroke, and traumatic brain injury. Epidemiologic panels were charged to complete the literature review for each disorder in order to estimate the 12-month prevalence, and health economic panels were charged to estimate best cost-estimates. A cost model was developed to combine the epidemiologic and economic data and estimate the total cost of each disorder in each of 30 European countries (EU27+Iceland, Norway and Switzerland). The cost model was populated with national statistics from Eurostat to adjust all costs to 2010 values, converting all local currencies to Euro, imputing costs for countries where no data were available, and aggregating country estimates to purchasing power parity adjusted estimates for the total cost of disorders of the brain in Europe 2010.Results The total cost of disorders of the brain was estimated at €798 billion in 2010. Direct costs constitute the majority of costs (37% direct healthcare costs and 23% direct non-medical costs) whereas the remaining 40% were indirect costs associated with patients' production losses. On average, the estimated cost per person with a disorder of the brain in Europe ranged between €285 for headache and €30,000 for neuromuscular disorders. The European per capita cost of disorders of the brain was €1550 on average but varied by country. The cost (in billion €PPP 2010) of the disorders of the brain included in this study was as follows: addiction: €65.7; anxiety disorders: €74.4; brain tumor: €5.2; child/adolescent disorders: €21.3; dementia: €105.2; eating disorders: €0.8; epilepsy: €13.8; headache: €43.5; mental retardation: €43.3; mood disorders: €113.4; multiple sclerosis: €14.6; neuromuscular disorders: €7.7; Parkinson's disease: €13.9; personality disorders: €27.3; psychotic disorders: €93.9; sleep disorders: €35.4; somatoform disorder: €21.2; stroke: €64.1; traumatic brain injury: €33.0. It should be noted that the revised estimate of those disorders included in the previous 2004 report constituted €477 billion, by and large confirming our previous study results after considering the inflation and population increase since 2004. Further, our results were consistent with administrative data on the health care expenditure in Europe, and comparable to previous studies on the cost of specific disorders in Europe. Our estimates were lower than comparable estimates from the US.Discussion This study was based on the best currently available data in Europe and our model enabled extrapolation to countries where no data could be found. Still, the scarcity of data is an important source of uncertainty in our estimates and may imply over- or underestimations in some disorders and countries. Even though this review included many disorders, diagnoses, age groups and cost items that were omitted in 2004, there are still remaining disorders that could not be included due to limitations in the available data. We therefore consider our estimate of the total cost of the disorders of the brain in Europe to be conservative. In terms of the health economic burden outlined in this report, disorders of the brain likely constitute the number one economic challenge for European health care, now and in the future. Data presented in this report should be considered by all stakeholder groups, including policy makers, industry and patient advocacy groups, to reconsider the current science, research and public health agenda and define a coordinated plan of action of various levels to address the associated challenges.Recommendations Political action is required in light of the present high cost of disorders of the brain. Funding of brain research must be increased; care for patients with brain disorders as well as teaching at medical schools and other health related educations must be quantitatively and qualitatively improved, including psychological treatments. The current move of the pharmaceutical industry away from brain related indications must be halted and reversed. Continued research into the cost of the many disorders not included in the present study is warranted. It is essential that not only the EU but also the national governments forcefully support these initiatives.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The economic costs of headaches are substantial, primarily manifesting as indirect and intangible costs. This includes work absences because of headaches (absenteeism), reduced on-the-job performance while experiencing headaches (presenteeism), reduced quality of life, and increased pain outside the workplace [5-7].”
In the citing paper
“Persistent depressive disorder (PDD) is characterized by psychosocial impairment (Angst et al. 2009; Gustavsson et al. 2011; Klein et al. 1988), high comorbidity (Köhler et al. 2019), low rates of spontaneous remission (McCullough et al. 1988) and poorer treatment outcomes compared to episodic depression (Stewart et al. 1989; Thase et al. 1994).”
From Reciprocal Dynamics of Therapeutic Alliance and Depressive Symptoms in Inpatient Cognitive Behavioural Analysis System of Psychotherapy: The Role of Attachment Insecurity. (2025) · cites this paper as Gustavsson et al. 2011
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,656
The Occurrence of Sleep-Disordered Breathing among Middle-Aged Adults
Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S., & Badr, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304293281704 · Cited by 10,183
Epidemiology of Obstructive Sleep Apnea: A Population Health Perspective
Young, T., Peppard, P. E., & Gottlieb, D. J. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2109080 · Cited by 4,244
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,032
Comprehensive Textbook of Psychiatry
Freedman, A. M., & Kaplan, H. I. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196712000-00052 · Cited by 3,825
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
Self-citationOosterhuis, H. (1997) · Cited by 2,397
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova‐Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,323
Epidemiology of Pervasive Developmental Disorders
Fombonne, E. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e31819e7203 · Cited by 1,971
Research works printed but not linked: 8
- Atance Martinez, 2004, Costs study in Alzheimer's disease, Rev. Clin. Esp., 204, 64
- Bertelli, 2009, New contributions of psychiatric research in the field of intellectual disabilities, Adv. Psychiatry, 3, 37
- Cavallo, 1997, The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy, Alzheimer Dis. Assoc. Disord., 11, 184
- Gessner, 1993, The cost of epilepsy in Switzerland, Int. J. Health Sci., 4, 121
- Mahdi-Rogers, 2008, Epidemiology and treatment of chronic inflammatory neuropathies in South East England, Eur. J. Neurol., 15
- Salize, 2004, Cost of care for depressive disorders in primary and specialized care in Germany, Psychiatr. Prax., 31, 147
- Wilms, 2004, Illness related costs for spouses of patients suffering from a mental illness: results of a study with repeated measurements, Psychiatr. Prax., 31, 177
- Wittchen, 2010, The timing of depression: an epidemiological perspective, Medicographia, 32, 155-125
Cited by
Sorted by citations
eQTLGen, Wray, N. R., 23andMe, the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E. M., Abdellaoui, A., Adams, M. J., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0090-3 · Cited by 3,005
Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research
Maas, A. I. R., Menon, D. K., Adelson, P. D., Andelic, N., Bell, M. J., Belli, A., Bragge, P., Brazinova, A., Büki, A., Chesnut, R. M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30371-x · Cited by 2,609
Katan, M., & Luft, A. (2018) · Seminars in Neurology · doi:10.1055/s-0038-1649503 · Cited by 2,137
European guideline for the diagnosis and treatment of insomnia
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., Espie, C. A., Garcia‐Borreguero, D., Gjerstad, M., Gonçalves, M., et al. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12594 · Cited by 2,049
Self-citationDefeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676
Self-citationScaling-up treatment of depression and anxiety: a global return on investment analysis
Chisholm, D., Sweeny, K., Sheehan, P., Rasmussen, B., Smit, F., Cuijpers, P., & Saxena, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30024-4 · Cited by 1,451
The economic cost of brain disorders in Europe
Olesen, J., Gustavsson, A., Svensson, M., Wittchen, H., & Jönsson, B. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03590.x · Cited by 1,560
Self-citationFilippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
A mega-analysis of genome-wide association studies for major depressive disorder
Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke, S., Wray, N. R., Lewis, C. M., Hamilton, S. P., Weissman, M. M., Breen, G., Byrne, E. M., Blackwood, D. H. R., Boomsma, D. I., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.21 · Cited by 1,120
Self-citationThe association between social relationships and depression: A systematic review
Santini, Z. I., Koyanagi, A., Tyrovolas, S., Mason, C., & Haro, J. M. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.12.049 · Cited by 949
Sleep, insomnia, and depression
Riemann, D. W., Krone, L. B., Wulff, K., & Nissen, C. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0411-y · Cited by 901
Machine Learning for Precision Psychiatry: Opportunities and Challenges
Bzdok, D., & Meyer‐Lindenberg, A. (2017) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2017.11.007 · Cited by 884
Trautmann, S., Rehm, J., & Wittchen, H. (2016) · The EMBO Reports · doi:10.15252/embr.201642951 · Cited by 798
Self-citationInflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond
Michopoulos, V., Powers, A., Gillespie, C. F., Ressler, K. J., & Jovanovic, T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.146 · Cited by 786
Jacobi, F., Höfler, M., Strehle, J., Mack, S., Gerschler, A., Scholl, L., Busch, M. A., Maske, U., Hapke, U., Gaebel, W., et al. (2014) · Der Nervenarzt · doi:10.1007/s00115-013-3961-y · Cited by 750
Self-citationAlonso, J., Liu, Z., Evans-Lacko, S., Sadikova, E., Sampson, N., Chatterji, S., Abdulmalik, J., Aguilar-Gaxiola, S., Al-Hamzawi, A., Andrade, L. H., et al. (2018) · Depression and Anxiety · doi:10.1002/da.22711 · Cited by 716
“4 billion for 30 European EU countries in 2010 (Gustavsson et al., 2011).”
InfluentialSelf-citationPenninx, B. W., Pine, D. S., Holmes, E. A., & Reif, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00359-7 · Cited by 740
SCOPE 2021: a new scorecard for osteoporosis in Europe
Kanis, J. А., Norton, N., Harvey, N. C., Jacobson, T., Johansson, H., Lorentzon, M., McCloskey, E. V., Willers, C., & Borgström, F. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-020-00871-9 · Cited by 782
Schnyder, N., Panczak, R., Groth, N., & Schultze-Lutter, F. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.189464 · Cited by 716
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 752
Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine
Gormley, P., Anttila, V., Winsvold, B. S., Palta, P., Esko, T., Pers, T. H., Farh, K.-H., Cuenca-León, E., Muona, M., Furlotte, N. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3598 · Cited by 690
Self-citationBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Self-citationThe Lancet Psychiatry Commission on psychological treatments research in tomorrow's science
Holmes, E. A., Ghaderi, A., Harmer, C. J., Ramchandani, P. G., Cuijpers, P., Morrison, A. P., Roiser, J. P., Bockting, C. L. H., O'Connor, R. C., Shafran, R., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30513-8 · Cited by 624
Amphetamine, past and present – a pharmacological and clinical perspective
Heal, D. J., Smith, S. L., Gosden, J., & Nutt, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482532 · Cited by 653
Solomou, I., & Constantinidou, F. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17144924 · Cited by 591
Cuijpers, P., Cristea, I. A., Karyotaki, E., Reijnders, M., & Huibers, M. J. H. (2016) · World Psychiatry · doi:10.1002/wps.20346 · Cited by 572
EPA guidance on the early intervention in clinical high risk states of psychoses
Schmidt, S. J., Schultze-Lutter, F., Schimmelmann, B. G., Maric, N. P., Salokangas, R. K. R., Riecher-Rössler, A., van der Gaag, M., Meneghelli, A., Nordentoft, M., Marshall, M., et al. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.013 · Cited by 585
Jacobi, F., Höfler, M., Siegert, J., Mack, S., Gerschler, A., Scholl, L., Busch, M. A., Hapke, U., Maske, U., Seiffert, I., et al. (2014) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1439 · Cited by 586
Self-citationHypothermia for Intracranial Hypertension after Traumatic Brain Injury
Andrews, P. J. D., Sinclair, H. L., Rodríguez, A., Harris, B. A., Battison, C. G., Rhodes, J. K. J., & Murray, G. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507581 · Cited by 583
Jacobi, F., Höfler, M., Strehle, J., Mack, S., Gerschler, A., Scholl, L., Busch, M. A., Maske, U., Hapke, U., Gäebel, W., et al. (2015) · Der Nervenarzt · doi:10.1007/s00115-015-4458-7 · Cited by 491
Self-citationPalfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 484
Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery
Oller‐Salvia, B., Sánchez‐Navarro, M., Giralt, E., & Teixidò, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 463
Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K. J., Craig, I. W., Anacker, C., Zunsztain, P. A., McGuffin, P., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.191 · Cited by 436
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“In addition to the personal suffering of patients, the economic burden caused by anxiety disorders is heavy (Gustavsson et al., 2011).”
BackgroundDoses of Neighborhood Nature: The Benefits for Mental Health of Living with Nature
Cox, D. T. C., Shanahan, D. F., Hudson, H. L., Plummer, K. E., SIRIWARDENA, G. M., Fuller, R. A., Anderson, K., Hancock, S., & Gaston, K. J. (2016) · BioScience · doi:10.1093/biosci/biw173 · Cited by 459
Physical Activity and Anxiety: A Systematic Review and Meta-analysis of Prospective Cohort Studies
McDowell, C. P., Dishman, R. K., Gordon, B. R., & Herring, M. P. (2019) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2019.05.012 · Cited by 385
Trasande, L., Zoeller, R. T., Hass, U., Kortenkamp, A., Grandjean, P., Myers, J. P., DiGangi, J., Bellanger, M. M., Hauser, R. B., Legler, J., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4324 · Cited by 382
A systematic review of randomised control trials on the effects of yoga on stress measures and mood
Pascoe, M. C., & Bauer, I. E. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.07.013 · Cited by 366
ESPEN guidelines on nutrition in dementia
Volkert, D., Chourdakis, M., Faxen-Irving, G., Frühwald, T., Landi, F., Suominen, M. H., Vandewoude, M., Wirth, R., & Schneider, S. M. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2015.09.004 · Cited by 442
Koutsouleris, N., Kambeitz-Ilankovic, L., Ruhrmann, S., Rosen, M., Ruef, A., Dwyer, D. B., Paolini, M., Chisholm, K., Kambeitz, J., Haidl, T., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.2165 · Cited by 341
S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen
Riemann, D. W., Baum, E., Cohrs, S., Crönlein, T., Hajak, G., Hertenstein, E., Klose, P., Langhorst, J., Mayer, G., Nissen, C., et al. (2017) · Somnologie - Schlafforschung und Schlafmedizin · doi:10.1007/s11818-016-0097-x · Cited by 352
Developmental epidemiology of anxiety disorders
Beesdo-Baum, K., & Knappe, S. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.05.001 · Cited by 330
Als, T. D., Kurki, M., Grove, J., Voloudakis, G., Therrien, K., Tasanko, E. M., Nielsen, T. T., Naamanka, J., Veerapen, K., Levey, D. F., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02352-1 · Cited by 332
Celada, P., Bortolozzi, A., & Artigas, F. (2013) · CNS Drugs · doi:10.1007/s40263-013-0071-0 · Cited by 323
Thelin, E. P., Nelson, D., & Bellander, B. (2016) · Acta Neurochirurgica · doi:10.1007/s00701-016-3046-3 · Cited by 318
History and future technical innovation in positron emission tomography
Jones, T., & Townsend, D. W. (2017) · Journal of medical imaging · doi:10.1117/1.jmi.4.1.011013 · Cited by 324
A direct test of the diathesis-stress model for depression
Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, Colodro-Conde, L., Couvy-Duchesne, B., Zhu, G., Coventry, W. L., Byrne, E. M., Gordon, S., Wright, M. J., Montgomery, G. W., Madden, P. A. F., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.130 · Cited by 285
Amin, F. M., Asghar, M. S., Hougaard, A., Hansen, A. E., Larsen, V. A., de Koning, P. J. H., Larsson, H. B. W., Olesen, J., & Ashina, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70067-x · Cited by 296
Self-citationEating disorders: the big issue
Schmidt, U., Adan, R. A. H., Boehm, I., Campbell, I. C., Dingemans, A. E., Ehrlich, S., Elzakkers, I. F. F. M., Favaro, A., Giel, K. E., Harrison, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00081-x · Cited by 292
The default mode network and recurrent depression: A neurobiological model of cognitive risk factors
Marchetti, I., Koster, E. H. W., Sonuga-Barke, E. J., & De Raedt, R. (2012) · Neuropsychology Review · doi:10.1007/s11065-012-9199-9 · Cited by 287
Bolea-Alamañac, B., Nutt, D. J., Adamou, M., Asherson, P., Bazire, S., Coghill, D., Heal, D., Müller, U., Nash, J., Santosh, P., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113519509 · Cited by 287
A narrative review on the burden of migraine: when the burden is the impact on people’s life
Leonardi, M., & Raggi, A. (2019) · The Journal of Headache and Pain · doi:10.1186/s10194-019-0993-0 · Cited by 303
Ettinger, U., Meyhöfer, I., Steffens, M., Wagner, M., & Koutsouleris, N. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00018 · Cited by 300
Fusar-Poli, P., Rocchetti, M., Sardella, A., Avila, A., Brandizzi, M., Caverzasi, E., Politi, P., Ruhrmann, S., & McGuire, P. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.157115 · Cited by 272
Intracerebral Hemorrhage, Oxidative Stress, and Antioxidant Therapy
Duan, X., Wen, Z., Shen, H., Shen, M., & Chen, G. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1203285 · Cited by 273
Music interventions for acquired brain injury
Magee, W. L., Clark, I. N., Tamplin, J., & Bradt, J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006787.pub3 · Cited by 274
The cost of mental disorders: a systematic review
Christensen, M. K., Lim, C. C. W., Saha, S., Plana‐Ripoll, O., Cannon, D., Presley, F., Weye, N., Momen, N. C., Whiteford, H., Iburg, K. M., et al. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602000075x · Cited by 263
Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis
Konnopka, A., & König, H. (2020) · PharmacoEconomics · doi:10.1007/s40273-019-00849-7 · Cited by 259
Giuliani, D., Ottani, A., Zaffe, D., Galantucci, M., Strinati, F., Lodi, R., & Guarini, S. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.05.006 · Cited by 254
The kynurenine pathway in schizophrenia and bipolar disorder
Erhardt, S., Schwieler, L., Imbeault, S., & Engberg, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.020 · Cited by 265
Nagl, M., Jacobi, C., Paul, M., Beesdo‐Baum, K., Höfler, M., Lieb, R., & Wïttchen, H. (2016) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-015-0808-z · Cited by 288
Self-citationGarcia‐García, Á. L., Newman‐Tancredi, A., & Leonardo, E. D. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3389-x · Cited by 260
Strategies to reduce wasteful spending: Turning the lens to hospitals and pharmaceuticals
OECD (2018) · Health at a glance. Europe · doi:10.1787/health_glance_eur-2018-5-en · Cited by 248
SCOPE: a scorecard for osteoporosis in Europe
Kanis, J. A., Borgström, F., Compston, J., Dreinhöfer, K., Nolte, E., Jönsson, L., Lems, W. F., McCloskey, E. V., Rizzoli, R., & Stenmark, J. (2013) · Archives of Osteoporosis · doi:10.1007/s11657-013-0144-1 · Cited by 246
Self-citationROCK inhibition in models of neurodegeneration and its potential for clinical translation
Koch, J. C., Tatenhorst, L., Roser, A.-E., Saal, K.-A., Tönges, L., & Lingor, P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.008 · Cited by 239
Wang, Z., Xiong, G., Tsang, W. C., Schätzlein, A. G., & Uchegbu, I. F. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.258152 · Cited by 247
Constraint-induced movement therapy for upper extremities in people with stroke
Corbetta, D., Sirtori, V., Castellini, G., Moja, L., & Gatti, R. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004433.pub3 · Cited by 248
Shame-proneness, guilt-proneness and anxiety symptoms: A meta-analysis
Cândea, D.-M., & Szentagotai-Tătar, A. (2018) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2018.07.005 · Cited by 230
AMPA receptor trafficking and the mechanisms underlying synaptic plasticity and cognitive aging
Henley, J. M., & Wilkinson, K. A. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.1/jhenley · Cited by 242
Astrocyte activation and reactive gliosis—A new target in stroke?
Pekny, M., Wilhelmsson, U., Tatlisumak, T., & Pekna, M. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.021 · Cited by 240
Ceña, V., & Játiva, P. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0139 · Cited by 232
Pain and the onset of depressive and anxiety disorders
Gerrits, M. M. J. G., van Oppen, P., van Marwijk, H., Penninx, B. W. J. H., & van der Horst, H. E. (2013) · Pain · doi:10.1016/j.pain.2013.09.005 · Cited by 242
Vismara, M., Caricasole, V., Starcevic, V., Cinosi, E., Dell'Osso, B., Martinotti, G., & Fineberg, N. A. (2020) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2020.152167 · Cited by 224
Mental health research priorities for Europe
Wykes, T., Haro, J. M., Belli, S. R., Obradors-Tarragó, C., Arango, C., Ayuso-Mateos, J. L., Bitter, I., Brunn, M., Chevreul, K., Demotes-Mainard, J., et al. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00332-6 · Cited by 218
Sander, L., Rausch, L., & Baumeister, H. (2016) · JMIR Mental Health · doi:10.2196/mental.6061 · Cited by 218
Schaller, S., Mauskopf, J., Kriza, C., Wahlster, P., & Kolominsky-Rabas, P. L. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4198 · Cited by 215
Brain-computer interface technologies: from signal to action
Ortiz-Rosario, A., & Adeli, H. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0032 · Cited by 215
The size, burden and cost of disorders of the brain in the UK
Fineberg, N. A., Haddad, P. M., Carpenter, L., Gannon, B., Sharpe, R., Young, A. H., Joyce, E. M., Rowe, J. B., Wellsted, D. M., Nutt, D., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113495118 · Cited by 232
Self-citationSchizophrenia--Time to Commit to Policy Change
Fleischhacker, W. W., Arango, C., Arteel, P., Barnes, T. R. E., Carpenter, W., Duckworth, K., Galderisi, S., Halpern, L., Knapp, M., Marder, S. R., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu006 · Cited by 214
Self-citationCrimes Against Minds: On Mental Manipulations, Harms and a Human Right to Mental Self-Determination
Bublitz, C., & Merkel, R. (2012) · Criminal Law and Philosophy · doi:10.1007/s11572-012-9172-y · Cited by 212
The polygenic architecture of schizophrenia — rethinking pathogenesis and nosology
Smeland, O. B., Frei, O., Dale, A. M., & Andreassen, O. A. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0364-0 · Cited by 211
High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases
Aldewachi, H. S., Al-Zidan, R. N., Conner, M. T., & Salman, M. M. (2021) · Bioengineering · doi:10.3390/bioengineering8020030 · Cited by 217
Iorfino, F., Scott, E. M., Carpenter, J. S., Cross, S. P., Hermens, D. F., Killedar, M., Nichles, A., Zmicerevska, N., White, D., Guastella, A. J., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.2360 · Cited by 188
Santini, Z. I., Fiori, K. L., Feeney, J. C., Tyrovolas, S., Haro, J. M., & Koyanagi, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.06.032 · Cited by 216
Contributions of Epidemiology to Our Understanding of Migraine
Merikangas, K. R. (2013) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12038 · Cited by 191
Optimizing treatment success in multiple sclerosis
Ziemssen, T., Derfuss, T. J., Stefano, N. D., Giovannoni, G., Palavra, F., Tomic, D., Vollmer, T., & Schippling, S. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7986-y · Cited by 191
The Cost of Brain Diseases: A Burden or a Challenge?
Luca, M. D., & Olesen, J. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.044 · Cited by 189
Self-citationTrasande, L., Zoeller, R. T., Hass, U., Kortenkamp, A., Grandjean, P., Myers, J. P., DiGangi, J., Hunt, P. M., Rudel, R. A., Sathyanarayana, S., et al. (2016) · Andrology · doi:10.1111/andr.12178 · Cited by 188
Childhood Trauma in Schizophrenia: Current Findings and Research Perspectives
Popovic, D., Schmitt, A., Kaurani, L., Senner, F., Papiol, S., Malchow, B., Fischer, A., Schulze, T. G., Koutsouleris, N., & Falkai, P. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00274 · Cited by 211
Stratified medicine for mental disorders
Schumann, G., Binder, E. B., Holte, A., de Kloet, E. R., Oedegaard, K. J., Robbins, T. W., Walker-Tilley, T. R., Bitter, I., Brown, V. J., Buitelaar, J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.010 · Cited by 186
Anxiety and depression in Nepal: prevalence, comorbidity and associations
Risal, A., Manandhar, K., Linde, M., Steiner, T. J., & Holen, A. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-0810-0 · Cited by 191
Self-citationShafiee, M., Arekhi, S., Omranzadeh, A., & Sahebkar, A. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.020 · Cited by 185
The role of neuroscience within psychology: A call for inclusiveness over exclusiveness.
Schwartz, S. J., Lilienfeld, S. O., Meca, A., & Sauvigné, K. C. (2016) · American Psychologist · doi:10.1037/a0039678 · Cited by 184
Hybrid carbon based nanomaterials for electrochemical detection of biomolecules
Laurila, T. T., Sainio, S., & Miguel, A. (2017) · Progress in Materials Science · doi:10.1016/j.pmatsci.2017.04.012 · Cited by 177
Kowal, M., Conroy, E., Ramsbottom, N., Smithies, T. D., Toth, A. J., & Campbell, M. J. (2021) · JMIR Serious Games · doi:10.2196/26575 · Cited by 215
Curcumin and neurodegenerative diseases
Monroy, A., Lithgow, G. J., & Alavez, S. (2013) · BioFactors · doi:10.1002/biof.1063 · Cited by 178
Winkler, P., Krupchanka, D., Roberts, T., Kondrátová, L., Machů, V., Höschl, C., Sartorius, N., van Voren, R., Aizberg, O., Bitter, I., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30135-9 · Cited by 173
Relapse rates after psychotherapy for depression – stable long-term effects? A meta-analysis
Steinert, C., Hofmann, M., Kruse, J., & Leichsenring, F. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.043 · Cited by 172
Metadata
- Authors
- Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., Gannon, B., Jones, D. H., Jennum, P., Jordanova, A., Jönsson, L., Karampampa, K., Knapp, M., Kobelt, G., Kurth, T., Lieb, R., Linde, M., Ljungcrantz, C., Maercker, A., Melin, B., Moscarelli, M., Musayev, A., Norwood, F., Preisig, M., Pugliatti, M., Rehm, J., Salvador-Carulla, L., Schlehofer, B., Simon, R., Steinhausen, H.-C., Stovner, L. J., Vallat, J.-M., den Bergh, P. V., van Os, J., Vos, P., Xu, W., Wittchen, H.-U., Jönsson, B., & Olesen, J.
- Affiliations
- Karlstad University (SE)
- Technische Universität Dresden (DE)
- Karolinska University Hospital (SE)
- Municipal Institute for Medical Research (ES)
- Mario Negri Institute for Pharmacological Research (IT)
- Philipps University of Marburg (DE)
- University of Florence (IT)
- Karolinska Institutet (SE)
- University of Leeds (GB)
- Glostrup Hospital (DK)
- University of Antwerp (BE)
- King's College London (GB)
- Lund University (SE)
- Harvard University (US)
- University of Basel (CH)
- Norwegian University of Science and Technology (NO)
- Umeå University (SE)
- King's College Hospital (GB)
- Centre Hospitalier Universitaire Vaudois (CH)
- University of Sassari (IT)
- German Cancer Research Center (DE)
- European Monitoring Centre for Drugs and Drug Addiction (PT)
- Aalborg University Hospital (DK)
- Centre Hospitalier Universitaire de Limoges (FR)
- Radboud University Nijmegen (NL)
- Stockholm School of Economics (SE)
- Corresponding author
- Olesen, Jes
- ORCID
- Gustavsson, Anders
- Svensson, Mikael
- Jacobi, Frank
- Alonso, Jordi
- Beghi, Ettore
- Dodel, Richard
- Ekman, Mattias
- Fratiglioni, Laura
- Gannon, Brenda
- Jennum, Poul
- Jordanova, Albena
- Jönsson, Linus
- Karampampa, Korinna
- Knapp, Martin
- Kobelt, Gisela
- Kurth, Tobias
- Lieb, Roselind
- Linde, Mattias
- Ljungcrantz, Christina
- Melin, Beatrice
- Moscarelli, Massimo
- Preisig, Martin
- Pugliatti, Maura
- Steinhausen, Hans-Christoph
- Stovner, Lars Jacob
- Vallat, Jean-Michel
- Xu, Weili
- Olesen, Jes
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 21
- Issue
- 10
- Pages
- 718-779
- ISSN
- 0924-977X (ISSN-L)
- OpenAlex
- W2131786905
- Cited by
- 1,723
- References
- 427
- Citations by year
- 2026: 42 · 2025: 64 · 2024: 70 · 2023: 88 · 2022: 100 · 2021: 133 · 2020: 123 · 2019: 120 · 2018: 233 · 2017: 130 · 2016: 141 · 2015: 142 · 2014: 124 · 2013: 118 · 2012: 81
- FWCI
- 145.35
- Type
- journal article
- Language
- en
- Open access
- green
- tud.qucosa.de
- Licence
- Locations
- European Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Qucosa (Saxon State and University Library Dresden) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- mental illness, neurological disorders, economic burden, prevalence, direct and indirect costs, cost model, Europe, brain tumors, dementia, epilepsy, multiple sclerosis, stroke, traumatic brain injury, Parkinson's disease, migraine, developmental disorders, neuromuscular disorders, sleep disorders, somatoform disorders, cost per person
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Mental Disorders, Brain Diseases, Child, Child, Preschool, Europe, Health Expenditures, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Public Health, Prevalence, Health Care Costs, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
